Familial Hemiplegic Migraine Approved Drugs
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Familial Hemiplegic Migraine.
Found 3 Approved Drugs for Familial Hemiplegic Migraine
SUMAtriptan
Brand Names
Migranow, Zembrace SymTouch, Onzetra Xsail, Tosymra, Imitrex, Treximet
SUMAtriptan
Brand Names
Migranow, Zembrace SymTouch, Onzetra Xsail, Tosymra, Imitrex, Treximet
Form: Spray, Injection, Tablet, Kit, Capsule, Solution
Method of administration: Subcutaneous, Nasal, Oral
FDA approval date: January 23, 1997
Classification: Serotonin-1b and Serotonin-1d Receptor Agonist
Sumatriptan injection, USP is indicated in adults for the acute treatment of migraine, with or without aura, and the acute treatment of cluster headache. Limitations of Use : Use only if a clear diagnosis of migraine or cluster headache has been established. If a patient has no response to the first migraine or cluster headache attack treated with sumatriptan injection, USP, reconsider the diagnosis before sumatriptan injection, USP is administered to treat any subsequent attacks. Sumatriptan injection, USP is not indicated for the prevention of migraine or cluster headache attacks. Sumatriptan injection, USP is a serotonin (5-HT 1B/1D ) receptor agonist (triptan) indicated for: Acute treatment of migraine with or without aura in adults ( 1 ) Acute treatment of cluster headache in adults ( 1 ) Limitations of Use : Use only if a clear diagnosis of migraine or cluster headache has been established ( 1 ) Not indicated for the prophylactic therapy of migraine or cluster headache attacks ( 1 )
Rizatriptan
Brand Names
Maxalt-Mlt, Rizafilm, Maxalt
Rizatriptan
Brand Names
Maxalt-Mlt, Rizafilm, Maxalt
Form: Tablet, Film
Method of administration: Oral
FDA approval date: June 25, 2012
Classification: Serotonin-1b and Serotonin-1d Receptor Agonist
Rizatriptan benzoate is a serotonin (5-HT) 1B/1D receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years of age ( 1 ) Limitations of Use: Use only after clear diagnosis of migraine has been established ( 1 ) Not indicated for the prophylactic therapy of migraine ( 1 ) Not indicated for the treatment of cluster headache ( 1 ) Rizatriptan benzoate tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. Limitations of Use Rizatriptan benzoate tablets should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with rizatriptan benzoate tablets, the diagnosis of migraine should be reconsidered before rizatriptan benzoate tablets are administered to treat any subsequent attacks. Rizatriptan benzoate tablets are not indicated for use in the management of hemiplegic or basilar migraine. Rizatriptan benzoate tablets are not indicated for the prevention of migraine attacks. Safety and effectiveness of rizatriptan benzoate tablets have not been established for cluster headache.
Ondansetron
Brand Names
Ondansetron ODT, Sumansetron
Ondansetron
Brand Names
Ondansetron ODT, Sumansetron
Form: Injection, Tablet, Kit, Solution
Method of administration: Oral, Intravenous, Intramuscular
FDA approval date: November 07, 2006
Classification: Serotonin-3 Receptor Antagonist
Ondansetron is indicated for the prevention of nausea and vomiting associated with: highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2. initial and repeat courses of moderately emetogenic cancer chemotherapy. radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. Ondansetron is also indicated for the prevention of postoperative nausea and/or vomiting. Ondansetron is a 5-HT 3 receptor antagonist indicated for the prevention of: nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m 2. nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. postoperative nausea and/or vomiting.
Showing 1-3 of 3
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances